{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:48:43Z","timestamp":1782978523966,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.oret.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:28:05Z","timestamp":1772641685000},"page":"726-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations between Systemic Tyrosine Kinase Inhibitors and Development of Age-Related Macular Degeneration in Patients with Cancer"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4074-1690","authenticated-orcid":false,"given":"Shirley","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7903-0792","authenticated-orcid":false,"given":"Hejin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2577-108X","authenticated-orcid":false,"given":"Hayden A.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-5395","authenticated-orcid":false,"given":"Nadia J.","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.02.018_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-9-23","article-title":"The secret life of kinases: functions beyond catalysis","volume":"9","author":"Rauch","year":"2011","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.oret.2026.02.018_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.oret.2026.02.018_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.oret.2026.02.018_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.oret.2026.02.018_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.oret.2026.02.018_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.oret.2026.02.018_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.survophthal.2021.05.007","article-title":"Retinal toxicities of systemic anticancer drugs","volume":"67","author":"Arora","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.018_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.oret.2026.02.018_bib9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/ijms22031170","article-title":"Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy","volume":"22","author":"Pugazhendhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oret.2026.02.018_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.oret.2026.02.018_bib11","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.oret.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(08)61759-6","article-title":"Age-related macular degeneration","volume":"372","author":"Coleman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.02.018_bib13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jamaophthalmol.2024.2376","article-title":"Janus kinase inhibitor therapy and risk of age-related macular degeneration in autoimmune disease","volume":"142","author":"Hallak","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.018_bib14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s11864-023-01149-1","article-title":"Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: clinical relevance, impact on outcome, preventive measures and treatment strategies","volume":"24","author":"Iurlo","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.oret.2026.02.018_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.6004\/jnccn.2023.7047","article-title":"Early increases in blood pressure and major adverse cardiovascular events in patients with renal cell carcinoma and thyroid cancer treated with VEGFR TKIs","volume":"21","author":"Narayan","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.oret.2026.02.018_bib16","article-title":"Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2026.02.018_bib17","doi-asserted-by":"crossref","first-page":"35181","DOI":"10.18632\/oncotarget.9285","article-title":"Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.oret.2026.02.018_bib18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/eye.2011.200","article-title":"Neurosensory retinal detachment due to sunitinib treatment","volume":"25","author":"Wegner","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.02.018_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/ICB.0b013e3182160965","article-title":"Bilateral central retinal vein occlusion in a patient with disseminated metastatic renal cell carcinoma treated with sorafenib","volume":"6","author":"Szczepanik","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2026.02.018_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/09273948.2022.2042318","article-title":"Bilateral central retinal vein occlusion associated with axitinib therapy: a case report","volume":"31","author":"Pyare","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oret.2026.02.018_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","article-title":"Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study","volume":"135","author":"Jackson","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.018_bib22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","article-title":"APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration","volume":"105","author":"Cohen","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.018_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0420.2007.01014.x","article-title":"Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment","volume":"86","author":"Kernt","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.018_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.02.018_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jleuko\/qiac016","article-title":"Ocular immune privilege and retinal pigment epithelial cells","volume":"113","author":"Du","year":"2023","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.oret.2026.02.018_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.oret.2026.02.018_bib27","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.drudis.2019.05.035","article-title":"Challenges and opportunities for drug delivery to the posterior of the eye","volume":"24","author":"Cabrera","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.oret.2026.02.018_bib28","first-page":"166","article-title":"The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits","volume":"20","author":"Soba\u0144ska","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.oret.2026.02.018_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jamia\/ocac020","article-title":"Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility","volume":"29","author":"Kukhareva","year":"2022","journal-title":"J Am Med Inform Assoc"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026000941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026000941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:27:21Z","timestamp":1782977241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2468653026000941"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.02.018","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between Systemic Tyrosine Kinase Inhibitors and Development of Age-Related Macular Degeneration in Patients with Cancer","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology, Inc.","name":"copyright","label":"Copyright"}]}}